<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02374047</url>
  </required_header>
  <id_info>
    <org_study_id>CAT-2054-101</org_study_id>
    <nct_id>NCT02374047</nct_id>
  </id_info>
  <brief_title>A 2-Part, Phase 1, Single and Multiple Ascending Dose Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of CAT-2054 in Healthy Subjects</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Catabasis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Catabasis Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a 2-part, Phase 1, placebo-controlled, double-blind, randomized, single and multiple
      ascending dose study. CAT-2054 will be administered either as an uncoated capsule (CAT-2054)
      or a coated capsule (CAT-2054-C). In Part A, CAT-2054 or placebo is administered as a single
      dose in a fasting state at 4 dose levels; at 3 dose levels, subjects will return for a second
      dose of the study drug after a high-fat meal. Additionally, at 1 dose level, CAT-2054-C or
      placebo will be administered as a single dose in a fasting state, and subjects will return
      for a second dose of the study drug after a high-fat meal. In Part B, CAT-2054 will be
      administered as multiple ascending doses at 4 dose levels for 14 consecutive days. In
      selected cohorts, CAT-2054, CAT-2054-C or CAT-2054 with atorvastatin will be dosed to assess
      safety in anticipation of future clinical trials.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2015</start_date>
  <completion_date type="Actual">July 2015</completion_date>
  <primary_completion_date type="Actual">July 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency and severity of adverse events</measure>
    <time_frame>up to 3 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUCinf of CAT-2054</measure>
    <time_frame>Days 1 through 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax of CAT-2054</measure>
    <time_frame>up to 3 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline for hematology, chemistry, coagulation and urinalysis</measure>
    <time_frame>up to 3 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess the pharmacodynamic effects of multiple doses of CAT-2054 on serum lipids LDL-C, non-HDL-C, total cholesterol, triglycerides, HDL-C, apoB, and PCSK9.</measure>
    <time_frame>up to 3 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC48 of Atorvastatin</measure>
    <time_frame>up to 3 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>12</number_of_arms>
  <enrollment type="Actual">118</enrollment>
  <condition>Hypercholesterolemia</condition>
  <arm_group>
    <arm_group_label>Cohort A1, Dose Level 1: CAT-2054 or placebo fasting</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort A2, Dose Level 2: CAT-2054 or placebo fasting and fed</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort A3, Dose Level 3: CAT-2054 or placebo fasting and fed</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort A4, Dose Level 4: CAT-2054 or placebo fasting and fed</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort A5, Dose Level 5: CAT-2054-C or placebo fasting and fed</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B1, Dose Level 1: CAT-2054 or placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple dose for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B2, Dose Level 2: CAT-2054 or placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple dose for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B3, Dose Level 3: CAT-2054 or placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple dose for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B4, Dose Level 4: CAT-2054 or placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple dose for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B5, Dose Level 5: CAT-2054 or placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple dose for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B6, Dose Level 6: CAT-2054 with atorvastatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple dose for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B7, Dose Level 7: CAT-2054 or placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple dose for 14 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CAT-2054</intervention_name>
    <arm_group_label>Cohort A1, Dose Level 1: CAT-2054 or placebo fasting</arm_group_label>
    <arm_group_label>Cohort A2, Dose Level 2: CAT-2054 or placebo fasting and fed</arm_group_label>
    <arm_group_label>Cohort A3, Dose Level 3: CAT-2054 or placebo fasting and fed</arm_group_label>
    <arm_group_label>Cohort A4, Dose Level 4: CAT-2054 or placebo fasting and fed</arm_group_label>
    <arm_group_label>Cohort B1, Dose Level 1: CAT-2054 or placebo</arm_group_label>
    <arm_group_label>Cohort B2, Dose Level 2: CAT-2054 or placebo</arm_group_label>
    <arm_group_label>Cohort B3, Dose Level 3: CAT-2054 or placebo</arm_group_label>
    <arm_group_label>Cohort B4, Dose Level 4: CAT-2054 or placebo</arm_group_label>
    <arm_group_label>Cohort B5, Dose Level 5: CAT-2054 or placebo</arm_group_label>
    <arm_group_label>Cohort B6, Dose Level 6: CAT-2054 with atorvastatin</arm_group_label>
    <arm_group_label>Cohort B7, Dose Level 7: CAT-2054 or placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Cohort A1, Dose Level 1: CAT-2054 or placebo fasting</arm_group_label>
    <arm_group_label>Cohort A2, Dose Level 2: CAT-2054 or placebo fasting and fed</arm_group_label>
    <arm_group_label>Cohort A3, Dose Level 3: CAT-2054 or placebo fasting and fed</arm_group_label>
    <arm_group_label>Cohort A4, Dose Level 4: CAT-2054 or placebo fasting and fed</arm_group_label>
    <arm_group_label>Cohort A5, Dose Level 5: CAT-2054-C or placebo fasting and fed</arm_group_label>
    <arm_group_label>Cohort B1, Dose Level 1: CAT-2054 or placebo</arm_group_label>
    <arm_group_label>Cohort B2, Dose Level 2: CAT-2054 or placebo</arm_group_label>
    <arm_group_label>Cohort B3, Dose Level 3: CAT-2054 or placebo</arm_group_label>
    <arm_group_label>Cohort B4, Dose Level 4: CAT-2054 or placebo</arm_group_label>
    <arm_group_label>Cohort B5, Dose Level 5: CAT-2054 or placebo</arm_group_label>
    <arm_group_label>Cohort B7, Dose Level 7: CAT-2054 or placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CAT-2054-C</intervention_name>
    <arm_group_label>Cohort A5, Dose Level 5: CAT-2054-C or placebo fasting and fed</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin</intervention_name>
    <arm_group_label>Cohort B6, Dose Level 6: CAT-2054 with atorvastatin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Provision of written informed consent before any study-specific procedure

          -  Good health as determined by medical history, physical examination, vital sign
             measurements, ECG, and clinical laboratory measurements

          -  Satisfies one of the following:

               1. Females not of childbearing potential: non-pregnant and non-lactating surgically
                  sterile or postmenopausal 2 years or less with a follicle-stimulating hormone
                  assessment greater than or equal to 40 IU/L

               2. Males: surgically sterile, abstinent, or subject or partner is utilizing an
                  acceptable contraceptive method during and 3 months after the last study dose

          -  For Part B only, measured at Screening: Fasting LDL-C ≥100 mg/dL; or (Cohort B6 only)
             fasting LDL-C ≥130 mg/dL

          -  Body mass index (BMI) between 18 and 30 kg/m², inclusive, for Part A and between 18
             and 40 kg/m², inclusive, for Part B, and body weight &gt;50 kg at Screening

        Exclusion Criteria:

          -  Use of prescription drugs or non-prescription drugs including herbals, and dietary
             supplements (including multivitamins and any product containing niacin or omega-3
             fatty acids above the Recommended Daily Allowance) within 2 weeks before dosing.
             Additionally for Part B only, use of any lipid-regulating prescription drug,
             non-prescription drug, herbal, or dietary supplement within 6 weeks before dosing

          -  Clinically significant disease that requires a physician's care and/or would interfere
             with study evaluations

          -  Clinically significant electrocardiogram (ECG) abnormalities or laboratory results as
             assessed by the investigator, such as QTcF &gt;450

          -  Use of any investigational drug or participation in any investigational study within
             30 days prior to screening or 5 half-lives of the study agent, whichever is longer
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Spaulding Clinical Research</name>
      <address>
        <city>West Bend</city>
        <state>Wisconsin</state>
        <zip>53095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 2, 2015</study_first_submitted>
  <study_first_submitted_qc>February 23, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 27, 2015</study_first_posted>
  <last_update_submitted>March 21, 2016</last_update_submitted>
  <last_update_submitted_qc>March 21, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 22, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin Calcium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

